

Abteilungsbesprechung März 2023

02.03.2022

Klinischer Teil:

ITP Expertenreport 2022

DOI: entfällt

Referentin: C. Unger

Wissenschaftlicher Teil:

Image-seq: spatially resolved single-cell sequencing guided by in situ and in vivo imaging

doi: 10.1038/s41592-022-01673-2

Referentin: Sina Sender

09.03.2023

Klinischer Teil:

Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus

DOI: <https://doi.org/10.1007/s00277-021-04746-y> Referentin: V. Zink

Wissenschaftlicher Teil:

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by
doi: 10.1182/bloodadvances.2022007364 Referentin: Sandra Lange

16.03.2023:

Klinischer Teil:

Vorstellung der Janssen – Hämatologie Pipeline

DOI: 10.1200/JCO.22.00392

Referent: Dr.med.
Angermund

Wissenschaftlicher Teil:

Non-viral precision T cell receptor replacement for personalized cell therapy

<https://doi.org/10.1038/s41586-022-05531-1>

Referent: Robby
Engelmann

23.03.2023:

Klinischer Teil:

Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study & Consensus Guideline for Use of Glucarpidase in Patients with High-DoseMethotrexate Induced Acute Kidney Injury and DelayedMethotrexate Clearance

DOI: 10.1177/10781552221079568 & Referentin: K. Müller
2018;23:52–61

Wissenschaftlicher Teil:

Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblast

DOI: 10.1186/s12943-022-01711-9 Referentin: Claudia Maletzki

30.03.2022:

Klinischer Teil:

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

DOI: <https://doi.org/10.1200/JCO.21.01604> Referent: H. Gläser

Wissenschaftlicher Teil:

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients W

DOI: 10.1200/JCO.21.02752 Referentin: Jana Scheffler

augmenting tumor cell phagocytosis

oma

ith Advanced KRASG12C Solid Tumors (KRYSTAL-1)